Hyperfractionated radiation therapy for locoregionally advanced nasopharyngeal cancer

Koichi Isobe, Takashi Uno, Hiroyuki Kawakami, Naoyuki Ueno, Takashi Aruga, Shigeo Yasuda, Toyoyuki Hanazawa, Yoshitaka Okamoto, Hisao Ito, Naoyuki Shigematsu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The purpose of this study is to clarify the efficacy and toxicity of hyperfractionated radiation therapy (RT) for patients with nasopharyngeal cancer (NPC). Methods: Twenty-two patients with NPC treated at our hospital between April 1994 and December 2002 were the subjects of this study. They received hyperfractionated RT with a fraction size of 1.2 Gy, with a median tumor dose of 72 Gy (range 64.8-80.4). During this study period, our institutional strategy for locoregionally advanced NPC included neoadjuvant or concurrent chemotherapy combined with hyperfractionated RT, and 17 patients received some forms of cisplatin-containing chemotherapy. Results: With a median follow-up of 59 months, the estimated 5-year disease-free survival rate and overall survival rate were 72.7 and 85.2%, respectively. Acute hematological toxicities were acceptable and manageable. However, >50% of patients required nutritional support, and experienced severe pharyngitis, skin reaction and body weight loss. With regard to late sequelae, one patient developed grade 3 osteomyelitis, and one patient each developed grade 4 passage disturbance and laryngeal edema. No patients experienced any grades of optic nerve injury or temporal lobe necrosis. Conclusions: Hyperfractionated RT using 1.2 Gy per fraction, for a total dose of 72 Gy, produces a comparable treatment outcome. Although deleterious neurological sequelae were not observed in this study, caution should be exercised regarding other late sequelae, such as osteomyelitis and passage disturbance.

Original languageEnglish
Pages (from-to)116-120
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume35
Issue number3
DOIs
Publication statusPublished - 2005 Mar

Fingerprint

Nasopharyngeal Neoplasms
Radiotherapy
Osteomyelitis
Survival Rate
Laryngeal Edema
Optic Nerve Injuries
Drug Therapy
Nutritional Support
Pharyngitis
Temporal Lobe
Cisplatin
Disease-Free Survival
Weight Loss
Necrosis
Body Weight
Skin

Keywords

  • Altered fractionation
  • Hyperfractionation
  • Late effect
  • Nasopharyngeal cancer (NPC)

ASJC Scopus subject areas

  • Oncology

Cite this

Hyperfractionated radiation therapy for locoregionally advanced nasopharyngeal cancer. / Isobe, Koichi; Uno, Takashi; Kawakami, Hiroyuki; Ueno, Naoyuki; Aruga, Takashi; Yasuda, Shigeo; Hanazawa, Toyoyuki; Okamoto, Yoshitaka; Ito, Hisao; Shigematsu, Naoyuki.

In: Japanese Journal of Clinical Oncology, Vol. 35, No. 3, 03.2005, p. 116-120.

Research output: Contribution to journalArticle

Isobe, K, Uno, T, Kawakami, H, Ueno, N, Aruga, T, Yasuda, S, Hanazawa, T, Okamoto, Y, Ito, H & Shigematsu, N 2005, 'Hyperfractionated radiation therapy for locoregionally advanced nasopharyngeal cancer', Japanese Journal of Clinical Oncology, vol. 35, no. 3, pp. 116-120. https://doi.org/10.1093/jjco/hyi041
Isobe, Koichi ; Uno, Takashi ; Kawakami, Hiroyuki ; Ueno, Naoyuki ; Aruga, Takashi ; Yasuda, Shigeo ; Hanazawa, Toyoyuki ; Okamoto, Yoshitaka ; Ito, Hisao ; Shigematsu, Naoyuki. / Hyperfractionated radiation therapy for locoregionally advanced nasopharyngeal cancer. In: Japanese Journal of Clinical Oncology. 2005 ; Vol. 35, No. 3. pp. 116-120.
@article{26a4a447b8564389aac02489df0ed965,
title = "Hyperfractionated radiation therapy for locoregionally advanced nasopharyngeal cancer",
abstract = "Objective: The purpose of this study is to clarify the efficacy and toxicity of hyperfractionated radiation therapy (RT) for patients with nasopharyngeal cancer (NPC). Methods: Twenty-two patients with NPC treated at our hospital between April 1994 and December 2002 were the subjects of this study. They received hyperfractionated RT with a fraction size of 1.2 Gy, with a median tumor dose of 72 Gy (range 64.8-80.4). During this study period, our institutional strategy for locoregionally advanced NPC included neoadjuvant or concurrent chemotherapy combined with hyperfractionated RT, and 17 patients received some forms of cisplatin-containing chemotherapy. Results: With a median follow-up of 59 months, the estimated 5-year disease-free survival rate and overall survival rate were 72.7 and 85.2{\%}, respectively. Acute hematological toxicities were acceptable and manageable. However, >50{\%} of patients required nutritional support, and experienced severe pharyngitis, skin reaction and body weight loss. With regard to late sequelae, one patient developed grade 3 osteomyelitis, and one patient each developed grade 4 passage disturbance and laryngeal edema. No patients experienced any grades of optic nerve injury or temporal lobe necrosis. Conclusions: Hyperfractionated RT using 1.2 Gy per fraction, for a total dose of 72 Gy, produces a comparable treatment outcome. Although deleterious neurological sequelae were not observed in this study, caution should be exercised regarding other late sequelae, such as osteomyelitis and passage disturbance.",
keywords = "Altered fractionation, Hyperfractionation, Late effect, Nasopharyngeal cancer (NPC)",
author = "Koichi Isobe and Takashi Uno and Hiroyuki Kawakami and Naoyuki Ueno and Takashi Aruga and Shigeo Yasuda and Toyoyuki Hanazawa and Yoshitaka Okamoto and Hisao Ito and Naoyuki Shigematsu",
year = "2005",
month = "3",
doi = "10.1093/jjco/hyi041",
language = "English",
volume = "35",
pages = "116--120",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Hyperfractionated radiation therapy for locoregionally advanced nasopharyngeal cancer

AU - Isobe, Koichi

AU - Uno, Takashi

AU - Kawakami, Hiroyuki

AU - Ueno, Naoyuki

AU - Aruga, Takashi

AU - Yasuda, Shigeo

AU - Hanazawa, Toyoyuki

AU - Okamoto, Yoshitaka

AU - Ito, Hisao

AU - Shigematsu, Naoyuki

PY - 2005/3

Y1 - 2005/3

N2 - Objective: The purpose of this study is to clarify the efficacy and toxicity of hyperfractionated radiation therapy (RT) for patients with nasopharyngeal cancer (NPC). Methods: Twenty-two patients with NPC treated at our hospital between April 1994 and December 2002 were the subjects of this study. They received hyperfractionated RT with a fraction size of 1.2 Gy, with a median tumor dose of 72 Gy (range 64.8-80.4). During this study period, our institutional strategy for locoregionally advanced NPC included neoadjuvant or concurrent chemotherapy combined with hyperfractionated RT, and 17 patients received some forms of cisplatin-containing chemotherapy. Results: With a median follow-up of 59 months, the estimated 5-year disease-free survival rate and overall survival rate were 72.7 and 85.2%, respectively. Acute hematological toxicities were acceptable and manageable. However, >50% of patients required nutritional support, and experienced severe pharyngitis, skin reaction and body weight loss. With regard to late sequelae, one patient developed grade 3 osteomyelitis, and one patient each developed grade 4 passage disturbance and laryngeal edema. No patients experienced any grades of optic nerve injury or temporal lobe necrosis. Conclusions: Hyperfractionated RT using 1.2 Gy per fraction, for a total dose of 72 Gy, produces a comparable treatment outcome. Although deleterious neurological sequelae were not observed in this study, caution should be exercised regarding other late sequelae, such as osteomyelitis and passage disturbance.

AB - Objective: The purpose of this study is to clarify the efficacy and toxicity of hyperfractionated radiation therapy (RT) for patients with nasopharyngeal cancer (NPC). Methods: Twenty-two patients with NPC treated at our hospital between April 1994 and December 2002 were the subjects of this study. They received hyperfractionated RT with a fraction size of 1.2 Gy, with a median tumor dose of 72 Gy (range 64.8-80.4). During this study period, our institutional strategy for locoregionally advanced NPC included neoadjuvant or concurrent chemotherapy combined with hyperfractionated RT, and 17 patients received some forms of cisplatin-containing chemotherapy. Results: With a median follow-up of 59 months, the estimated 5-year disease-free survival rate and overall survival rate were 72.7 and 85.2%, respectively. Acute hematological toxicities were acceptable and manageable. However, >50% of patients required nutritional support, and experienced severe pharyngitis, skin reaction and body weight loss. With regard to late sequelae, one patient developed grade 3 osteomyelitis, and one patient each developed grade 4 passage disturbance and laryngeal edema. No patients experienced any grades of optic nerve injury or temporal lobe necrosis. Conclusions: Hyperfractionated RT using 1.2 Gy per fraction, for a total dose of 72 Gy, produces a comparable treatment outcome. Although deleterious neurological sequelae were not observed in this study, caution should be exercised regarding other late sequelae, such as osteomyelitis and passage disturbance.

KW - Altered fractionation

KW - Hyperfractionation

KW - Late effect

KW - Nasopharyngeal cancer (NPC)

UR - http://www.scopus.com/inward/record.url?scp=20244367614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244367614&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyi041

DO - 10.1093/jjco/hyi041

M3 - Article

C2 - 15741300

AN - SCOPUS:20244367614

VL - 35

SP - 116

EP - 120

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 3

ER -